FDA Advisory Panel to review Medtronic's Endeavor Drug-Eluting Stent on 10 October 2007

12/09/2007

Biocompatibles International plc (LSE:BII), a leading medical technology company focused on drug device Combination Products principally for use in oncology, is pleased to reproduce below an announcement made today by Medtronic in respect of its Endeavor® Drug-Eluting Stent programme.

Biocompatibles earns a royalty of 1.5% on world-wide sales of the Endeavor stent.

“Medtronic, Inc., announced today that a U.S. Food and Drug Administration (FDA) Advisory Panel will review the Premarket Approval (PMA) application for the company’s Endeavor® Drug-Eluting Coronary Stent on October 10.

The FDA’s Circulatory System Devices Panel is scheduled to meet October 10 and 11. Endeavor is the only drug eluting stent on the agenda for review during the October 10 panel meeting.

The Endeavor PMA sets a new standard for clinical data submitted to the FDA, with data from the largest, most wide-ranging patient population and for patients with the longest follow-up ever submitted to support the safety and efficacy of a new drug-eluting stent (DES). Medtronic’s PMA submission includes compelling evidence characterizing the long-term safety and efficacy of the Endeavor DES. Medtronic will present data on more than 4,100 patients who have been treated with the Endeavor DES in clinical trials that include follow up for as long as four years; 675 of these patients have been followed for three years and more and 1,287 for two years or more. These data constitute a robust body of evidence for the panel’s review.”

Ends

Media Resource

Notes to Editors

Glossary of Terms

Medtronic, Inc.
The full text of the Medtronic announcements can be accessed at www.medtronic.com